Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part, Non-Randomised, Open Label Study to Evaluate the Effect of Itraconazole, Rifampicin, Rabeprazole, and Omeprazole on the Pharmacokinetics of KD025

Trial Profile

A Two-Part, Non-Randomised, Open Label Study to Evaluate the Effect of Itraconazole, Rifampicin, Rabeprazole, and Omeprazole on the Pharmacokinetics of KD025

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs KD 025 (Primary) ; Itraconazole; Rabeprazole; Rifampicin
  • Indications Graft-versus-host disease; Idiopathic pulmonary fibrosis; Plaque psoriasis; Scleroderma
  • Focus Pharmacokinetics
  • Sponsors Kadmon Corporation
  • Most Recent Events

    • 11 Oct 2018 Number of treatment arms has been increased hence number of patients has also increased. Endpoints has also added.
    • 11 Oct 2018 Planned number of patients changed from 40 to 78.
    • 11 Oct 2018 Planned End Date changed from 20 Jul 2018 to 15 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top